Skip to main content

The yearly conference brings together leaders throughout the world who are dedicated to advancing treatment options for Alzheimer’s disease (AD). This year, Jim Hendrix presented the LIFE-DSR blood biomarker data at (Clinical Trials in Alzheimer’s Disease) CTAD’s November 2020 digital conference. The LIFE-DSR study is an ongoing natural history study designed to better understand the factories that underlie symptoms of clinical presentation of Down syndrome associated AD (DS-AD). The COVID pandemic provided an opportunity to conduct early analyses on neurodegenerative biomarkers P-tau181, P-tau217 and NfL.

Click on image to download a PDF.

Learn more about the LuMind IDSC Foundation and Eli Lilly and Company partnership.